Get the Stockscreener App
4.18
14.84%
0.54
Precigen Inc stock is traded at $4.18, with a volume of 24.16M.
It is up +14.84% in the last 24 hours and up +175.00% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$3.64
Open:
$3.65
24h Volume:
24.16M
Relative Volume:
4.43
Market Cap:
$1.25B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-10.72
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+42.18%
1M Performance:
+175.00%
6M Performance:
+118.85%
1Y Performance:
+273.21%
1-Day Range:
$3.62
$4.205
1-Week Range:
$2.62
$4.205
52-Week Range:
$0.6513
$4.205
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.18 | 879.02M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment - Yahoo Finance
Precigen Enters Commercial Supply Agreement with Catalent - MSN
Precigen files to sell 143.81M shares of common stock for holders - MSN
Precigen Stock Surges After FDA Approval of Papzimeos - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Precigen stock By Investing.com - Investing.com Australia
PGEN: JMP Securities Raises Price Target, Maintains Rating | PGEN Stock News - GuruFocus
Precigen stock rises as H.C. Wainwright reiterates Buy rating on FDA approval - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Precigen stock - Investing.com
Precigen Inc. Stock Approaches Key Moving AverageEarnings Performance Report & Weekly High Return Opportunities - sundaytimes.kr
Precigen Reports Q2 2025 Earnings: Loss Widens Amid High R&D Spend, Market Reacts Strongly to Surprises - AInvest
Trends in pharma deals — a BioCentury podcast - BioCentury
Precigen signs supply agreement with Catalent for PAPIZEMOS manufacturing - Investing.com
Citizens JMP raises Precigen stock price target to $8 on RRP treatment pricing - Investing.com
Technical Heatmap Flags Precigen Inc. for WatchWeekly Earnings Recap & Daily Profit Maximizing Trade Tips - newsimpact.co.kr
Germantown biopharma Precigen scores first-ever FDA approval - The Business Journals
Growth or Bubble? Decoding PGEN’s Rapid Rise - StocksToTrade
PGEN’s Roller Coaster Ride: What’s Next? - StocksToTrade
Transcript : Precigen, Inc.Special Call - MarketScreener
Precigen’s PAPZIMEOS Receives FDA Approval for RRP - TipRanks
Precigen secures full USFDA nod for Papzimeos for adults with Recurrent Respiratory Papillomatosis - Medical Dialogues
Can Precigen Inc. Rally Enough to Break EvenWeekly Investment Summary & Community Verified Swing Trade Signals - newsimpact.co.kr
What makes Precigen Inc. stock price move sharply2025 Big Picture & Safe Capital Growth Plans - thegnnews.com
Precigen Stock Surges as FDA Approves Papzimeos Drug - timothysykes.com
Morning Movers: Precigen surges following full FDA approval of Papzimeos - MSN
Quant Funds Rotate Into Precigen Inc. StockJuly 2025 Closing Moves & AI Driven Stock Price Forecasts - metal.it
FDA approves Precigen immunotherapy for respiratory papillomatosis - MSN
Precigen upgraded to Neutral from Underweight at JPMorgan - MSN
Precigen's FDA Approval of PAPZIMEOS: A Game-Changer for the RRP Market and a Catalyst for Shareholder Value - AInvest
US Stocks Mixed as Evolv Technologies, Precigen, Hesai Group, and Others Surge - AInvest
Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility - insights.citeline.com
US FDA approves Precigen’s immunotherapy for rare respiratory disease - WTVB
Prasad signals flexibility with Precigen decision, but will it generalize? - BioCentury
Market Today: UnitedHealth Soars on Berkshire Stake, Precigen Surges on FDA Approval - GuruFocus
Healthcare Stocks Rally After Berkshire’s UnitedHealth Bet - Finimize
Precigen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN) - Seeking Alpha
Precigen, Inc. Stock (PGEN) Opinions on FDA Approval of Papzimeos - Quiver Quantitative
FDA Grants Full Approval to Precigen’s Papzimeos for Recurrent Respiratory Papillomatosis - PharmExec
Target, Precigen, Natgas companies - TradingView
Precigen shares jump after US FDA approves first therapy for rare respiratory disease - Reuters
Precigen soars on full FDA approval of Papzimeos - The Pharma Letter
Precigen's PGEN Soars 59.5% on Historic FDA Approval—What's Next for This Biotech Breakout? - AInvest
Precigen stock soars after FDA approves first RRP treatment - Investing.com
A speedy FDA approval for Precigen’s rare disease gene therapy - BioWorld MedTech
Big Stocks Move Higher on Friday: Evolv Technologies, Precigen, Hesai Group, and More - AInvest
Precigen shares surge 55.14% intraday after FDA approval of Papzimeos for recurrent respiratory papillomatosis. - AInvest
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday - Benzinga
Precigen's 73% Surge: A Biotech Breakthrough or a Volatility Play? - AInvest
Precigen’s Remarkable Uptick: What Drives It? - StocksToTrade
US FDA approves Precigen's immunotherapy for rare respiratory disease - Reuters
Why Is Precigen Stock Surging On Friday?Precigen (NASDAQ:PGEN) - Benzinga
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):